Holen Sie sich die Stockscreener-App
13.72
4.25%
-0.63
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51 - TradingView
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
Technical Reactions to JANX Trends in Macro Strategies - Stock Traders Daily
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring A 376% Upside In Biotechnology - DirectorsTalk Interviews
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
Why analysts remain bullish on Janux Therapeutics Inc. stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - mfd.ru
Where is Janux Therapeutics (JANX) Headed According to Analysts? - Finviz
Janux Therapeutics (JANX) Expected to Announce Earnings on Thursday - MarketBeat
Janux therapeutics doses first participant in JANX011 phase 1 trial By Investing.com - Investing.com Australia
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - BioSpace
Janux therapeutics doses first participant in JANX011 phase 1 trial - Investing.com Nigeria
Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011 - TradingView
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - AOL.com
Published on: 2026-02-15 18:41:23 - mfd.ru
Trading the Move, Not the Narrative: (JANX) Edition - Stock Traders Daily
Is Janux Therapeutics Inc. forming a bullish divergenceQuarterly Risk Review & Risk Controlled Stock Pick Alerts - mfd.ru
What is Janux Therapeutics Inc.’s valuation compared to sectorMarket Performance Recap & Low Drawdown Momentum Trade Ideas - mfd.ru
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags - Yahoo! Finance Canada
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowShould You Sell? - MarketBeat
(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance UK
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Insider Monkey
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance UK
Why is Janux Therapeutics Inc. stock going downPortfolio Value Report & Weekly High Conviction Trade Ideas - mfd.ru
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st
4.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):